The M&A team advised Centerview Partners LLC and Guggenheim Securities, LLC as financial advisors to Soleno Therapeutics, Inc. (Nasdaq: SLNO) in connection with its definitive agreement to be acquired by Neurocrine Biosciences, Inc. (Nasdaq: NBIX) for $53.00 per share in cash, representing a total transaction equity value of approximately $2.9 billion. Under the terms of the agreement, Neurocrine will commence a cash tender offer to acquire all outstanding shares of Soleno, followed by a second-step merger in which any remaining shares will be converted into the right to receive the same cash consideration, subject to customary closing conditions including regulatory approvals.
The Goodwin team was led by Stuart Cable, Rob Masella, Blake Liggio, and Amanda Gill.
For additional information, please read the press release.